Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopurine Reintroduction in IBD Pancreatitis
NCT02281799Phase 4Withdrawn
- Sponsor
- Shaare Zedek Medical Center
- Start
- Mar 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azathioprine and mercaptopurine in inflammatory bowel disease (IBD), sponsored by Shaare Zedek Medical Center. Primary endpoint: Number of participants demonstrating biochemical or clinical evidence of pancreatitis at 3 months. Planned start Mar 2015; status: withdrawn.
02
Drugs
azathioprinemercaptopurine
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02281799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281799.